SNTI — Senti Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $11.16m
- -$12.46m
- $2.56m
- 19
- 36
- 20
- 14
Annual cashflow statement for Senti Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21.2 | -19.9 | -55.3 | -58.2 | -71.1 |
| Depreciation | |||||
| Non-Cash Items | 0.895 | -3.1 | 19.3 | 8.01 | 10.4 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.46 | -1.77 | 0.615 | 13.9 | 4.67 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -18.4 | -24.2 | -34.6 | -34.9 | -52.4 |
| Capital Expenditures | -2 | -1.16 | -5.54 | -41.4 | -12 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5.75 | 12.5 | — | -40.6 | 42.1 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 3.75 | 11.4 | -5.54 | -82 | 30.1 |
| Financing Cash Flow Items | -0.019 | -0.282 | -0.065 | 117 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14 | 38.1 | 68.4 | 119 | 0.779 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.615 | 25.2 | 28.3 | 1.7 | -21.5 |